Evidence map›Paper›PMID 38977895›Full record

ArticleCancer gene therapy2024

Long-term severe hypoxia adaptation induces non-canonical EMT and a novel Wilms Tumor 1 (WT1) isoform.

Jordan Quenneville, Albert Feghaly, Margaux Tual, Kiersten Thomas, François Major, Etienne Gagnon

Abstract read
In one paragraph

Article in Cancer gene therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jordan QuennevilleInstitute for Research in Immunology and Cancer, Université de Montréal, Montréal, QC, Canada. jquennev@gmail.com.ORCID 0009-0000-1498-6614
Albert FeghalyInstitute for Research in Immunology and Cancer, Université de Montréal, Montréal, QC, Canada.ORCID 0000-0001-7929-415X
Margaux TualInstitute for Research in Immunology and Cancer, Université de Montréal, Montréal, QC, Canada.
Kiersten ThomasDepartment of Integrative Oncology, BC Cancer Research Center, Vancouver, BC, Canada.
François MajorInstitute for Research in Immunology and Cancer, Université de Montréal, Montréal, QC, Canada.
Etienne GagnonInstitute for Research in Immunology and Cancer, Université de Montréal, Montréal, QC, Canada. etienne.gagnon@umontreal.ca.ORCID 0000-0001-5815-9768

Funding

Cancer Research Society (Société de Recherche sur le Cancer) 20464CIHRGouvernement du Canada | Canadian Institutes of Health Research (Instituts de Recherche en Santé du Canada) MOP133726
6 · The paper itself

Abstract

The majority of cancer deaths are caused by solid tumors, where the four most prevalent cancers (breast, lung, colorectal and prostate) account for more than 60% of all cases (1). Tumor cell heterogeneity driven by variable cancer microenvironments, such as hypoxia, is a key determinant of therapeutic outcome. We developed a novel culture protocol, termed the Long-Term Hypoxia (LTHY) time course, to recapitulate the gradual development of severe hypoxia seen in vivo to mimic conditions observed in primary tumors. Cells subjected to LTHY underwent a non-canonical epithelial to mesenchymal transition (EMT) based on miRNA and mRNA signatures as well as displayed EMT-like morphological changes. Concomitant to this, we report production of a novel truncated isoform of WT1 transcription factor (tWt1), a non-canonical EMT driver, with expression driven by a yet undescribed intronic promoter through hypoxia-responsive elements (HREs). We further demonstrated that tWt1 initiates translation from an intron-derived start codon, retains proper subcellular localization and DNA binding. A similar tWt1 is also expressed in LTHY-cultured human cancer cell lines as well as primary cancers and predicts long-term patient survival. Our study not only demonstrates the importance of culture conditions that better mimic those observed in primary cancers, especially with regards to hypoxia, but also identifies a novel isoform of WT1 which correlates with poor long-term survival in ovarian cancer.

Indexed as

Epithelial-Mesenchymal TransitionProtein IsoformsWT1 ProteinsCell Line, TumorGene Expression Regulation, NeoplasticHumansNeoplasmsProtein IsoformsWT1 protein, humanWT1 Proteins

Identifiers

PMID38977895
PMCPMC11327107

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.